Table 1.

Assessments and follow-up

Procedures	Data	Screening	Baseline	Treatment phase		Event based
			Face-to-face visit 1	Follow-up (min = 32 month, max = 91 months) No visits
				Linkage	Patient questionnaire (6 monthly)
Eligibility assessment		√
Informed consent			√
Randomisation			√
Demographics	Age, sex, ethnicity, marital status, education level, smoking history		√
Clinical (1)	Primary renal disease, date first seen by a nephrologist, co-morbidities, dietary restrictions, 24-h urine volume		√
Clinical (2)	RRT treatment history, prescribed medication (including erythropoiesis-stimulating agents and phosphate binders)		√	√
Physical assessment (1)	Height, heart rate		√
Physical assessment (2)	Weight, systolic and diastolic blood pressure		√	√
Resource use (1)	Day case and inpatient hospital admissions (including surgical procedures performed)		√	√
Resource use (2)	Nursing home/residential home days/hospice days, other hospital out-patient services and primary care and community services in the last 6 months		√		√
Laboratory tests	Creatinine, urea, Kt/V, urea reduction ratio, albumin, haemoglobin, haematocrit, mean corpuscular volume, sodium, potassium, bicarbonate, corrected calcium, phosphate, C-reactive protein, intact parathyroid hormone, total cholesterol. (From the date of the study visit or the closest date prior to the study visit)		√	√
Patient reported	EQ-5D-5L and DSI and time to recovery [31]		√		√
SAE reporting						√